lipegfilgrastim 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
granulocyte colony stimulating factor (G-CSF) type substances 4991 1117844-87-7

Description:

MoleculeDescription

Synonyms:

  • lipegfilgrastim
  • lonquex
  • XM22
A long acting glyco-pegylated recombinant form of human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Similar to G-CSF, lipegfilgrastim binds to and activates specific cell surface receptors, and stimulates neutrophil progenitor proliferation and differentiation. Therefore, this agent may prevent the duration and incidence of chemotherapy-induced neutropenia. Compared to filgrastim, lipegfilgrastim has a prolonged plasma half-life.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

DoseUnitRoute
0.30 mg P

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
July 25, 2013 EMA Sicor Biotech UAB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Thrombocytopenia 135.54 55.22 69 1596 208656 90418126
Hemianopia 117.99 55.22 22 1643 2060 90624722
Febrile neutropenia 110.41 55.22 55 1610 158294 90468488
Neutropenia 64.69 55.22 44 1621 224860 90401922
Post-traumatic pain 60.21 55.22 10 1655 478 90626304
Leukopenia 55.67 55.22 30 1635 100680 90526102

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Anal inflammation 158.04 55.68 33 1921 2196 42617185
SARS-CoV-2 test negative 153.55 55.68 31 1923 1744 42617637
Accident 132.40 55.68 35 1919 6468 42612913
Proctalgia 120.06 55.68 33 1921 7060 42612321
Haemorrhoids 99.05 55.68 35 1919 17062 42602319
Body temperature increased 85.86 55.68 33 1921 20325 42599056
Febrile neutropenia 84.84 55.68 69 1885 185634 42433747
Neutropenia 80.53 55.68 69 1885 199362 42420019
General physical health deterioration 68.54 55.68 56 1898 151190 42468191
Testicular germ cell cancer metastatic 61.98 55.68 9 1945 65 42619316

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 160.93 46.00 110 3532 316657 110269000
Anal inflammation 159.08 46.00 32 3610 2464 110583193
Thrombocytopenia 158.23 46.00 113 3529 348772 110236885
Neutropenia 157.78 46.00 116 3526 374504 110211153
SARS-CoV-2 test negative 151.62 46.00 30 3612 2123 110583534
Accident 121.09 46.00 34 3608 10918 110574739
Proctalgia 106.08 46.00 32 3610 13190 110572467
Hemianopia 92.64 46.00 21 3621 2847 110582810
General physical health deterioration 88.50 46.00 88 3554 425207 110160450
Leukopenia 83.24 46.00 55 3587 148736 110436921
Haemorrhoids 81.74 46.00 34 3608 35638 110550019
Testicular germ cell cancer metastatic 65.06 46.00 9 3633 64 110585593
Body temperature increased 61.99 46.00 32 3610 54681 110530976
Pyrexia 54.57 46.00 102 3540 898163 109687494
Post-traumatic pain 53.52 46.00 10 3632 521 110585136
Seminoma 52.53 46.00 9 3633 285 110585372
Diarrhoea 49.89 46.00 113 3529 1139392 109446265
Anaemia 47.57 46.00 73 3569 547013 110038644
Chills 46.21 46.00 43 3599 190537 110395120

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L03AA14 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
IMMUNOSTIMULANTS
IMMUNOSTIMULANTS
Colony stimulating factors
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

L03AA Colony stimulating factors 6 drugs
efbemalenograstim alfaeflapegrastimfilgrastimlenograstimpegfilgrastimsargramostim

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Chemotherapy-induced neutropenia indication 425229001




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Granulocyte colony-stimulating factor receptor Membrane receptor ACTIVATOR DRUG LABEL DRUG LABEL

External reference:

IDSource
4AWF0N6QV3 UNII
D10242 KEGG_DRUG
C3640212 UMLSCUI
CHEBI:757744 CHEBI
CHEMBL4594230 ChEMBL_ID
DB13200 DRUGBANK_ID
9342 INN_ID
C455861 MESH_SUPPLEMENTAL_RECORD_UI
1440046 RXNORM
015533 NDDF
1268483008 SNOMEDCT_US
710282003 SNOMEDCT_US
612596 PUBCHEM_CID

Pharmaceutical products:

None